Related Experiment Video

Updated: Sep 17, 2025

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.4K

PKIB facilitates bladder cancer proliferation and metastasis through mediation of HSP27 phosphorylation by PKA

Xiaolong Liu1, Xiaoyu Yin2, Feng Yuan3

  • 1Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China. lxl_2005@yeah.net.

Cell Death & Disease
|July 2, 2025
PubMed

Insights

Protein Kinase Inhibitor Beta (PKIB) promotes bladder cancer (BLCA) growth by inhibiting protein kinase A (PKA). MYCN enhances PKIB expression, revealing a new oncogenic pathway and potential therapeutic targets for BLCA.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cyclic AMP-dependent protein kinase A (PKA) plays a role in cancer.
  • Protein Kinase Inhibitor Beta (PKIB) inhibits PKA but its role in human cancers is not fully understood.

Purpose of the Study:

  • To investigate the role and mechanism of PKIB in bladder cancer (BLCA).

Main Methods:

  • Analyzed PKIB expression in BLCA.
  • Assessed the effects of PKIB on BLCA cell proliferation, migration, and invasion in vitro.
  • Evaluated the tumorigenic potential of PKIB in vivo.
  • Investigated the impact of PKIB on PKA activity and HSP27 phosphorylation.
  • Examined the regulation of PKIB expression by MYCN.

Main Results:

  • PKIB expression is elevated in BLCA and correlates with increased cell proliferation, migration, and invasion.
  • PKIB inhibits PKA activity, leading to reduced phosphorylation of HSP27.
  • MYCN directly binds to the PKIB promoter, upregulating its expression in BLCA.

Conclusions:

  • PKIB exhibits oncogenic properties in BLCA by disrupting PKA signaling.
  • MYCN-driven PKIB upregulation represents a novel oncogenic pathway in BLCA.
  • PKIB and its regulatory pathway present potential therapeutic targets for bladder cancer.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K